Luye Pharma Announces 2023 Financial Results：Showing solid sales growth and improved financial structure
Shanghai, March 27, 2024 – Luye Pharma Group (2186.HK) today announced its 2023 financial results and latest developments.
During the reporting period, the group's revenue was approximately RMB 6.14 billion, up 2.7 percent year-over-year, EBITDA was approximately RMB 2.08 ...
March 27,2024
Luye Pharma’s Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao
- Reshaping the landscape for the second-line treatments of Small Cell Lung Cancer -
Hong Kong and Macao, March 7, 2024 – A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong Cancer Therapy Society (HKCTS) with support from Luye ...
March 07,2024
04
2024-03
First Patient Enrolled for Phase 3 Clinical Study of Luye Pharma’s Irinotecan Hydrochloride Liposome Injection (LY01610)
05
2024-02
Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea
13
2023-12
Luye Pharma’s Innovative Formulations Baituowei and Rykindo Included on China’s 2023 National Reimbursement Drug List
12
2023-12
Luye Pharma Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong
04
2023-12
Luye Pharma Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Macao
31
2023-10
Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease
09
2023-10
NDA for Luye Pharma’s Paliperidone Palmitate Extended-release Injectable Suspension Submitted in the U.S.
07
2023-09
The World’s Only Goserelin Microsphere Formulation (Baituowei) Approved in China for the New Indication of Breast Cancer
29
2023-08
Luye Pharma Announces 2023 Half Year Results
21
2023-08
Luye Pharma Files NDA for Lurbinectedin in Macao for the Treatment of Relapsed SCLC
